Skip to content

Study · Randomized controlled trial · n = 152 · 2005

3 results

Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis.

Bagger YZ, Tankó LB, Alexandersen P, Karsdal MA, Olson M, Mindeholm L, Azria M, Christiansen C

Bone1 Sept 2005Cited by 81 (Europe PMC)

PMID16005273 (opens in a new tab)DOI10.1016/j.bone.2005.04.032 (opens in a new tab)PepBankPUB-16005273
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, oral salmon calcitonin with Eligen carrier significantly reduced urinary CTX-II excretion in a dose-dependent manner.

    In plain wordsIn postmenopausal women, oral salmon calcitonin with Eligen carrier significantly reduced urinary CTX-II excretion in a dose-dependent manner.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseUrinary CTX-II
    Study

    n = 152

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.15, 0.4, 1.0, or 2.5 mg · oral · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    sCT induced a significant dose-dependent decrease in 24-h urinary CTX-II excretion.
    2 context sentences
    Summary · context
    This was a randomized, double blind, placebo-controlled clinical setting including 152 Danish postmenopausal women aged 55-85.
    Summary · context
    The subjects received treatment with the different doses of sCT (0.15, 0.4, 1.0, or 2.5 mg) combined with Eligen technology-based carrier molecule (200 mg), or placebo for 3 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, oral salmon calcitonin with Eligen carrier reduced urinary CTX-I excretion in a dose-dependent manner.

    In plain wordsIn postmenopausal women, oral salmon calcitonin with Eligen carrier reduced urinary CTX-I excretion in a dose-dependent manner.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseUrinary CTX-I
    Study

    n = 152

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.15, 0.4, 1.0, or 2.5 mg · oral · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Similar dose-dependent responses were found in 24-h urinary CTX-I.
    2 context sentences
    Summary · context
    This was a randomized, double blind, placebo-controlled clinical setting including 152 Danish postmenopausal women aged 55-85.
    Summary · context
    The subjects received treatment with the different doses of sCT (0.15, 0.4, 1.0, or 2.5 mg) combined with Eligen technology-based carrier molecule (200 mg), or placebo for 3 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    After 3 months, women with the highest cartilage turnover receiving 1.0 mg oral salmon calcitonin with Eligen carrier had the greatest urinary CTX-II decrease.

    In plain wordsWomen with the highest cartilage turnover receiving 1.0 mg oral salmon calcitonin with Eligen carrier had the greatest urinary CTX-II decrease.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseUrinary CTX-II in highest-turnover subgroup
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1.0 mg · oral · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Women who received 1.0 mg of sCT and had the highest cartilage turnover presented the greatest decrease in urinary CTX-II after 3 months of treatment.
    2 context sentences
    Summary · context
    This was a randomized, double blind, placebo-controlled clinical setting including 152 Danish postmenopausal women aged 55-85.
    Summary · context
    The subjects received treatment with the different doses of sCT (0.15, 0.4, 1.0, or 2.5 mg) combined with Eligen technology-based carrier molecule (200 mg), or placebo for 3 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.